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Abstract
Background: The efficacy and safety of a dietary supplement derived from South American botanicals was compared
to glucosamine sulfate in osteoarthritis subjects in a Mumbai-based multi-center, randomized, double-blind study.
Methods: Subjects (n = 95) were screened and randomized to receive glucosamine sulfate (n = 47, 1500 mg/day) or
reparagen (n = 48, 1800 mg/day), a polyherbal consisting of 300 mg of vincaria (Uncaria guianensis) and 1500 mg of RNI
249 (Lepidium meyenii) administered orally, twice daily. Primary efficacy variable was response rate based on a 20%
improvement in WOMAC pain scores. Additional outcomes were WOMAC scores for pain, stiffness and function, visual
analog score (VAS) for pain, with assessments at 1, 2, 4, 6 and 8 weeks. Tolerability, investigator and subject global
assessments and rescue medication consumption (paracetamol) were measured together with safety assessments
including vital signs and laboratory based assays.
Results: Subject randomization was effective: age, gender and disease status distribution was similar in both groups. The
response rates (20% reduction in WOMAC pain) were substantial for both glucosamine (89%) and reparagen (94%) and
supported by investigator and subject assessments. Using related criteria response rates to reparagen were favorable
when compared to glucosamine. Compared to baseline both treatments showed significant benefits in WOMAC and VAS
outcomes within one week (P < 0.05), with a similar, progressive improvement over the course of the 8 week treatment
protocol (45–62% reduction in WOMAC or VAS scores). Tolerability was excellent, no serious adverse events were
noted and safety parameters were unchanged. Rescue medication use was significantly lower in the reparagen group (p
< 0.01) at each assessment period. Serum IGF-1 levels were unaltered by treatments.
Conclusion: Both reparagen and glucosamine sulfate produced substantial improvements in pain, stiffness and function
in subjects with osteoarthritis. Response rates were high and the safety profile was excellent, with significantly less rescue
medication use with reparagen. Reparagen represents a new natural productive alternative in the management of joint
health.
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Background
Osteoarthritis is a debilitating condition that is of growing
concern and significance given shifts in population pro-
files towards the aged in most developed countries [1,2].
In addition to demographic considerations, osteoarthritis
remains a therapeutic challenge and it is not uncommon
for patients to complement a pharmaceutical approach
with nutraceuticals, herbals, acupuncture and other com-
plementary medicine modalities [3-5]. While the current
pharmaceutical options, usually non-steroidal anti-
inflammatory drugs (NSAIDs), primarily focus on symp-
tom relief [6,7], some complementary medicines have the
potential to alter the disease process [5,8,9]. The current
goals are to limit or retard joint destruction, however the
ultimate therapeutic endpoint is to achieve restoration of
joint form and function.
Glucosamine, alone or with the more complex form of
matrix, chondroitin, is the most commonly used
nutraceutical option, and has been subject to significant
scrutiny [10]. Two recent large studies, the Glucosamine/
Chondroitin Arthritis Intervention Trial (GAIT) and the
Glucosamine Unum In Die (once a day) Efficacy (GUIDE)
have yielded conflicting results [11,12]. The GAIT study
used glucosamine hydrochloride administered three
times a day and did not yield positive endpoints when
compared to placebo [9]. Glucosamine hydrochloride is
less commonly used than glucosamine sulfate and lacks
supportive evidence for efficacy [13,14]. On the other
hand, the once-a-day regimen of glucosamine sulfate in
the GUIDE study, demonstrated significant improve-
ments over placebo control [12]. The glucosamine sulfate
formulation is more popular and is approved as a pre-
scription formulation in Europe. Additionally, several
long-term studies indicate that it may potentially delay,
unlike NSAIDs, structural changes to the joint in osteoar-
thritis [8,9]. Nevertheless, efficacy and response rates to
glucosamine and other treatment modalities are variable
[14,15] and we remain distant from the goal of defining
safe interventions that improve joint architecture. Glu-
cosamine while regarded as safe does have potential com-
plications for some individuals that limit its use [15,16].
As the majority of glucosamine is produced from seafood
sources there is a concern for potential allergic responses.
Nevetheless glucosamine is generally considered safe
although there is debate as to whether glucosamine may
promote insulin resistance, raise glucose levels or vascular
perturbations that may accelerate atherosclerosis [16-19].
This has contributed to the search for additional options.
To this end we have been evaluating botanicals that may
offer a disease modifying approach based on their redox
related actions on gene expression. Reparagen®, is a poly-
herbal based on a blend of extracts from an Amazonian
tea (Uncaria guianensis) and an Andean vegetable (Lepid-
ium meyenii), that has a unique profile and mechanism of
action [20]. Extracts of Uncaria guianensis have been
shown to suppress NF-κB, a transcription factor that regu-
lates a multitude of cytokines, chemokines, and enzymes
that contribute to the inflammatory process [21-24]. Tra-
ditionally used in the Amazon and South America for
arthritis and other forms of chronic inflammation, we
have demonstrated that low doses (100 mg/day) of vin-
caria offer rapid symptomatic relief of osteoarthritis [25].
The present trial is an extension of that observation using
a three fold higher dose and an additional value added
ingredient RNI 249 that promotes cartilage production of
IGF-1 [20]. These actions of RNI 249, observed in human
cartilage explants, were enhanced by co-administration of
vincaria [20]. This preclinical research and development
was funded by the National Institutes of Health (USA,
R43 AG024733-01), and resulted in the investigational
product used in this trial.
IGF-1 is an anabolic growth factor that contributes to car-
tilage repair and growth [26-30]. Inflammation sup-
presses the local expression of IGF-1 in cartilage
[20,26,27,29], as in other tissues [31-34], resulting in a
catabolic state and impaired tissue repair [31-36]. Thus,
therapies that either directly replenish cartilage IGF-1 lev-
els or enhance local IGF-1 production offer a potential
new approach to improving joint health. Glucosamine
has been postulated to limit cartilage degradation at high
concentrations (mM) in cartilage explants [37,38], but in
contrast to reparagen, glucosamine also appears to reduce
anabolic processes together with catabolic pathways, sug-
gesting that its potential for cartilage matrix repair may be
limited [37].
This preliminary clinical investigation was not designed to
evaluate improvements joint architecture; it was too brief
for a meaningful evaluation. However, the focus was to
determine in a controlled clinical investigation if repara-
gen offered relief of osteoarthritis symptoms, using glu-
cosamine sulfate as the comparator. The protocol was for
two months, but was highly detailed within that design
with assessments at weeks 1, 2, 4, 6 and 8 in addition to
the entry and baseline measurements. Safety metrics were
also assessed at these time-points (vital signs) and labora-
tory tests at the beginning and conclusion of the study.
Methods
Research Design
This randomized, double-blind, positive control, multi-
center trial was performed in Mumbai, India with
approval by the Institutional Ethics Committee of the K.J.
Somaiya Medical College & Hospital, and was in compli-
ance with the Helsinki Declaration.BMC Complementary and Alternative Medicine 2007, 7:34 http://www.biomedcentral.com/1472-6882/7/34
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Participants
Subjects were recruited from six centers in Mumbai, India.
These centers represent a combination of hospitals and
clinics specializing in orthopedics. Inclusion criteria were
ambulatory, adult patients of either sex and greater than
20 years of age with mild to moderate osteoarthritis as
determined by radiological examination and ARA func-
tional class II or III, and Kellgren Lawrence classification
grade II or grade III, and a baseline functional assessment
of overall pain of at ≥40 mm and ≤80 mm, on a 100 mm
Visual Analog Scale (VAS).
Exclusion criteria were: existence of other forms of arthri-
tis, arthroscopy of either knee within the past year, admin-
istration of intra-articular steroids with the past 3 months
or hyaluronic acid in the last 9 months, pregnancy or lac-
tating women or women not taking adequate birth con-
trol measures, presence of any concomitant unstable
disease or abnormality of any clinically relevant labora-
tory test, evidence of severe renal or hematologic disease,
cardiac insufficiency, moderate to severe neuropathy, and
unwillingness to come to regular follow-up visits for the
length of the study.
A Fixed Allocation Randomization procedure using an
algorithm was used to assign interventions to the partici-
pants with a pre-specified probability and on a per project
basis after subjects passed the screening procedures.
Treatments
The duration of treatment was 8 weeks, with either glu-
cosamine sulfate (1500 mg) or reparagen (1800 mg) both
administered as two capsules, twice a day orally before
meals. Glucosamine sulfate 2 KCl (99.1% purity) was sup-
plied by a local manufacturer (Healers Nutraceuticals, Pvt.
Ltd., Chennai, India) and reparagen was supplied by Rain-
forest Nutritionals, Inc. (Raleigh, NC, USA). The twice a
day dosing regimen was chosen to facilitate compliance
within the target population. Previously glucosamine sul-
fate has been shown to be effective when administered
using either at once and three times a day dosing regimens
[8,9,12,39-42] suggesting that the timing of administra-
tion is not a constraint for efficacy. Ethnomedical evi-
dence related to the constituents within reparagen favor
twice a day administration, and given these issues, twice a
day dosing was chosen to be optimal. The rescue medica-
tion was paracetamol (acetominophen) provided as 500
mg tablet, with daily dosing not to exceed 3 tablets a day
(1500 mg) for the first 4 weeks and 2 tablets (1000 mg)
for the last 4 weeks. A framework for the present trial was
a previous trial in osteoarthritis with the vincaria compo-
nent alone [25], administered at a three-fold lower dose
(100 mg). This former study demonstrated significant
improvements in pain within one week, with progressive
improvements over the four week treatment protocol
[25].
The test agent Reparagen® is a proprietary blend of two
natural products – vincaria (300 mg) and RNI 249 (1500
mg). Vincaria is an extract of Uncaria guianensis that is tra-
ditionally used to treat chronic inflammation including
arthritis [43]. RNI 249 is an extract of Lepidium meyenii, an
Andean vegetable and food staple in the Cruciferous fam-
ily. This vegetable has been harvested for nearly 6000
years to manage the health compromising effects of high
altitude [44,45].
Uniformity was maintained in both treatment groups in
terms of capsule weight, size, color, bottle filling, labeling,
and packaging. Treatments were packaged in red gelatin
capsules and packaged in wide mouthed white, opaque
bottles with screw caps in a clean room. Investigators were
provided with blinding chits containing patient codes
along with their treatment group (alphabetical). In case of
a serious adverse event investigators were instructed to
inform the monitors and then only unblind the treatment
group of the subject if the event appeared to be agent
related in order to address the necessary treatment. Com-
pliance was manually checked by study monitors by way
of pill count (study and rescue medication)
Primary Efficacy Variable – Response to Treatment
We used a modified version of the WOMAC (Western
Ontario and McMaster) Universities Osteoarthritis Index
as a disease-specific measure of health status. The changes
reflect the specific needs and cultural considerations of
this population and have been detailed before [46]. There
are three sections that deal with pain (5 questions), stiff-
ness (2 questions), and function or performance (21
questions). Each question had a response on a scale of 0 –
4, with 0 representing none, 1 slight, 2 moderate, 3 severe,
4 extreme.
As reported in the GAIT clinical trial investigating glu-
cosamine hydrochloride and chondroitin sulfate in oste-
oarthritis subjects [11], we used response rate to treatment
as a primary efficacy variable based on the WOMAC A or
pain criteria. For a subject to be deemed a responder there
must be a 20% reduction in their basal WOMAC pain
score [11]. In addition, given that this criteria is not strin-
gent we sought additional metrics based on alleviation of
WOMAC or VAS assessments of pain to determine if a
subject responded to therapy. These included (1) a 50%
reduction of WOMAC pain score (2) a combination of a
20 mm reduction in VAS pain and a 50% reduction in
WOMAC pain assessments (3) a 10 mm reduction in VAS
pain measurements and a 20% reduction in WOMAC
pain assessments. These additional metrics are similar to
the OMERACT-OARSI criteria with the exception thatBMC Complementary and Alternative Medicine 2007, 7:34 http://www.biomedcentral.com/1472-6882/7/34
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these normally include a VAS for function as well as pain.
However, in this study we only used a VAS approach for
pain and not function and so we limited the possible
responder entry criteria to pain metrics.
Secondary Efficacy Variables
A VAS (visual analog score) assessment of pain was
included as a secondary efficacy variable. With this assess-
ment a line of 100 mm is drawn to measure the individu-
als pain status, with 0 representing no pain, and 100 being
unbearable pain. Patients marked on this line the relevant
amount of pain they were experiencing and the value was
noted by the investigator, in mm.
The individual components of the WOMAC scale – pain,
function, performance and total were used as secondary
outcome assessments. Treatment effectiveness was
assessed by both investigators and subjects using a scale
that incorporated the following elements: Excellent –
complete relief of symptoms; Good – partial relief of
symptoms; Fair – minimal relief of symptoms; Poor – no
relief of symptoms; Very Poor – worsening of symptoms.
Tolerability was assessed in three categories. Good – no
side effects; Fair – mild to moderate side-effects; Poor –
severe side-effects and withdrawal of therapy. Measure-
ments of these secondary efficacy variables were made at
the end of the treatment protocol.
Rescue Medicine Consumption
Paracetamol was used as the rescue medication and dis-
pensed as 500 mg tablets with a maximum of 3 tablets
allotted per day for the first 4 weeks, and 2 tablets per day
for the last 4 weeks. Subjects were required to return the
paracetamol containers at each follow-up visit for count-
ing and renewal for the next phase of the study. Instruc-
tions were to use paracetamol strictly for rescue purposes.
This dose of paracetamol (1500 to 1000 mg) per day was
substantially less than the 4000 mg maximum allowed in
the GAIT study [11] and the 3000 mg used as an investi-
gational arm of the GUIDE study [12]. This was approved
by the institutional review board. The advantage of this
approach is that it helped to diminish the complication
that rescue medication may exert on the observations.
Serum IGF-1
While not a primary or secondary efficacy variable, serum
IGF-1 levels were measured in each subject before and at
the conclusion of the trial. The rationale for this measure-
ment was based on our preliminary ex vivo work with
human cartilage, inflammatory cytokines and reparagen
[20]. Blood was drawn between 8 and 10 in the morning,
and subjects were not fasted.
Data Quality Assurance
All investigators were informed of ICH-GCP guidelines.
Data quality, study execution monitoring was performed
by individuals independent of subject contact and treat-
ment assessment.
Statistical Analysis
Data was analyzed by a statistician who was blind to treat-
ments using the following tests – Chi squared test,
ANOVA, paired and unpaired t tests, Bonferroni, Dun-
nett's and Tukey's test as appropriate. SPSS 11.5, PEPI, EPI
INFO 2000 and MS Excel. Statistical significance was
taken at the 95% confidence level. Results are expressed as
the mean ± SEM. All efficacy analyses were performed on
an intention-to-treat basis. Safety metrics were assessed on
a paired basis (baseline and completion of the protocol).
Results
Patient Randomization and Disposition
Descriptions of the entry profile for subjects in each treat-
ment group are contained within Table 1, and demon-
strate an effective randomization process. Reflecting the
general demographic profile of the osteoarthritis, the
majority of the subjects were female: glucosamine (75%),
reparagen (75%). Age was also comparable in both treat-
ment groups (glucosamine 55.1 ± 1.6 years, reparagen
51.9 ± 1.8 years).
Disease status upon entry was also effectively randomized
between groups (Table 1) using both ARA Functional
Class and Kellgren Lawrence Criteria grade as the means
for quantifying disease severity. Both measurements
revealed that the majority of subjects had grade II disease,
and this was similar in both treatment groups. Using Chi
Table 1: Baseline characteristics of treatment groups
Glucosamine Reparagen
N Started (completed) 47 (41) 48 (38)
Age (years) 55.1 ± 1.6 51.9 ± 1.8
Gender (F:M %) 75 : 25 75 : 25
ARA Functional Class II:III, % 79 : 21 71 : 29
Kellgren Lawrence Criteria 
Grade 2:3, %
79 : 21 75 : 25
Screening
WOMAC Pain 8.1 ± 0.4 8.9 ± 0.5
WOMAC Stiffness 3.8 ± 0.2 4.0 ± 0.2
WOMAC Function 35.4 ± 2.0 37.2 ± 1.8
WOMAC Total 47.1 ± 2.5 50.1 ± 2.3
VAS Pain 65.4 ± 1.7 65.6 ± 1.5
Data expressed as a % of total or mean ± SEM. None of the entry 
assessments were significantly different between the glucosamine 
sulfate or reparagen groups.BMC Complementary and Alternative Medicine 2007, 7:34 http://www.biomedcentral.com/1472-6882/7/34
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square analysis no statistical difference in the entry disease
status was evident amongst the treatment groups using
either Kellgren Lawrence or ARA Functional Criteria.
Drop-outs from the study were similar in both groups,
disposition of subjects are described in Figure 1. There
were some drop-outs due to lack of efficacy and pain asso-
ciated with the condition between baseline measurements
and the first two weeks of treatment. Subsequent losses
were largely due to a failure to come for follow-up or for
unrelated conditions and adverse events necessitating
withdrawal. These adverse events were deemed to be unre-
lated to the treatments and included single cases of acci-
dent, loose bowel motions, hepatitis, gastric ulcer and
viral fever. In the glucosamine group a serious adverse
event at week 6, specifically gallstones requiring surgery
and this was deemed to be unrelated to the treatment. In
the glucosamine group 87% of the recruited subjects suc-
cessfully completed the study, and for reparagen 79%
completed the study.
Safety Variables – Laboratory
All laboratory tests were unchanged from baseline values
to week 8 for both treatment groups with the following
exception: there was a slight reduction in ESR at week 8 in
the reparagen treated group (p = 0.02), however the values
remained within normal limits for this population and
the result was viewed as not being clinically relevant.
Details of all assessments are described in Table 2.
Safety Variables – Vital Signs
Blood pressure, respiration rate and pulse rate were meas-
ured at screening, baseline, and at weeks 1, 2, 4, 6 and 8
of treatment. Results are depicted in Table 3. Using
ANOVA there was no significant alterations of these val-
ues with treatment.
Primary Efficacy Variable – Response to Treatment
Response rate was calculated in accordance with the
method described in the GAIT study [11]. This method
uses a 20% reduction in WOMAC pain as the primary
assessment of a response to treatment. Using this criteria
both treatments were associated with a large proportion
of responders within one week of treatment (reparagen
47.9%; glucosamine 46.8%). Response to both treat-
ments continued to increase for the duration of the study
protocol (Fig. 2). At week 4 the response rates were similar
with both treatments: reparagen 81.2%, glucosamine
74.5% and at the conclusion of the study at week 8: repar-
agen 93.7%, glucosamine 89.4% (Table 4).
We also used a more rigorous assessment of response rates
based on WOMAC pain scales than that used in the GAIT
study [11], specifically a 50% reduction in WOMAC pain
as the definition of a response to treatment as opposed to
a 20% reduction (Table 4). Using this more stringent
assessment the response rate to reparagen was signifi-
cantly greater than glucosamine at week 4 (p = 0.05) but
not at week 8.
We also sought to determine response rates to treatment
using the response criteria similar to that outlined by
OMERACT-OARSI [11,12]. However, as VAS measures
were for pain and not pain and function, these assess-
ments do not follow the precise OMERACT-OARSI crite-
ria. Nevertheless they provide a useful tool for assessing
response rates, in addition to the approaches described
above. Two levels of response were calculated based on a
combination of WOMAC and VAS metrics of pain and
results are summarized in Table 4. Firstly the more rigor-
ous criteria for response to treatment was determined by a
subject experiencing a 50% improvement in WOMAC
pain subscale and a reduction of VAS pain by 20 mm.
Using this criteria response rates tended to be greater for
reparagen but differences were not significant (Table 4).
The second level of determining response rates was less
rigorous, similar to the GAIT criteria, and used a 20%
reduction in WOMAC pain subscale and a 10 mm reduc-
tion in VAS pain. Similar trends to the other criteria were
Study profile including enrollments and outcomes Figure 1
Study profile including enrollments and outcomes.
DISPOSITION OF STUDY SUBJECTS
109 Patients Screened 
95 Randomized
47 Assigned to 
Glucosamine Sulphate
48 Assigned to Reparagen
41 Completed Study
6 Discontinued from Study:
4 Adverse Event
1 Lack of Efficacy
1 Unable to come for follow up
38 Completed Study
10 Discontinued from Study:
3 Adverse Event
2 Lack of Efficacy
2 Unable to come for follow up
3 Lost to Follow Up
14 ExcludedBMC Complementary and Alternative Medicine 2007, 7:34 http://www.biomedcentral.com/1472-6882/7/34
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noted (Table 4). These metrics of response to therapy indi-
cate that both reparagen and glucosamine sulfate pro-
duced time-dependent response rates based on
improvements in pain assessments (WOMAC and VAS).
Secondary Efficacy Variable – WOMAC
Baseline disease activity as defined by WOMAC pain (Fig
3), stiffness (Fig 4) and function or performance (Fig 5),
or total WOMAC scores (Fig. 6) were comparable and not
significantly different in the glucosamine or reparagen
treatment groups. With both treatments these assessments
were significantly improved within one week of treatment
(p < 0.05) for the individual components of WOMAC –
pain, stiffness, function (Figs. 3, 4, 5) or the total WOMAC
assessment (Fig. 6) with the following exceptions. The
glucosamine sulfate group did not achieve a significant
reduction in WOMAC stiffness scores until week 2. It is
also clear that with continued administration of the test
agents there were steady improvements in these assess-
ments of disease activity (p < 0.001, repeated measures
ANOVA). However, there were no significant differences
in the magnitude of these changes between the two treat-
ment groups; both treatments producing comparable
benefits over the course of this investigation.
For WOMAC pain scores the overall benefit was a 60%
reduction for glucosamine and 62% for reparagen. For
WOMAC stiffness scores were reduced with glucosamine
by 61% reduction and reparagen 51% at the end of 8
weeks of treatment. For WOMAC functional assessments,
glucosamine elicited a 62% improvement from baseline
and reparagen 61% at 8 weeks. Similarly, responses to
treatment as defined by percentage reduction in Total
WOMAC scores were similar for glucosamine (58%) and
reparagen (60%).
Secondary Efficacy Variable – VAS Pain
Pain status in the glucosamine and reparagen groups as
determined by VAS, were comparable at recruitment
(Table 1) and baseline (Fig. 7). Treatment resulted in a
reduction in VAS pain scores, with significance noted at
week 1 in both treatment groups (p < 0.05), and a steady
further decline in VAS pain values over the 8 week course
of treatment (Fig. 7). At the conclusion of the study there
was a 49% reduction in VAS pain in the glucosamine
group and a 45% reduction in the reparagen group. There
was no significant difference between the reparagen and
glucosamine groups in the magnitude of changes in the
VAS assessment of pain.
Table 3: Vital Signs
Vital Signzz Glucosamine Wk. 0 Glucosamine Wk. 8 Reparagen Wk. 0 Reparagen Wk. 8
Pulse Rate 76.0 ± 1.0 76.8 ± 0.7 78.1 ± 1.2 75.4 ± 1.0
Systolic BP 130 ± 3 128 ± 2 128 ± 2 127 ± 1
Diastolic BP 8 1  ±  18 0  ±  18 3  ±  18 1  ±  1
Respiration Rate 17.8 ± 0.4 17.7 ± 0.4 17.3 ± 0.3 17.9 ± 0.4
Data expressed as a mean ± SEM. Units of measure were: Pulse rate (beats per min), systolic and diastolic blood pressure (BP, mm Hg), respiration 
rate (breaths per minute). There were no significant differences between baseline and week 8 values with these treatments. As the analysis is on a 
paired basis before and after completing the protocol the analysis is per protocol, glucosamine n = 41, reparagen n = 38.
Table 2: Laboratory-based evaluations of safety
Test Glucosamine Wk. 0 Glucosamine Wk. 8 Reparagen Wk. 0 Reparagen Wk. 8
Neutrophils % 63.46 ± 1.25 63.54 ± 1.26 62.19 ± 1.32 62.38 ± 1.27
Lymphocytes % 31.73 ± 1.21 32.00 ± 1.27 32.27 ± 1.18 32.27 ± 1.21
Monocytes % 1.17 ± 0.14 1.32 ± 0.15 1.11 ± 0.13 1.16 ± 0.15
Eosinophils % 3.54 ± 0.36 3.22 ± 0.30 4.11 ± 0.47 3.19 ± 0.41
Basophils % 0.02 ± 0.02 0 ± 0 0 ± 0 0 ± 0
White blood cells mm3 7929 ± 268 7515 ± 222 7753 ± 303 7496 ± 262
Red Blood Cells mm3 4.06 ± 0.10 4.04 ± 0.08 4.13 ± 0.11 4.15 ± 0.08
Hemoglobin gm/dl 12.02 ± 0.3 12.00 ± 0.2 11.84 ± 0.3 11.92 ± 0.2
Erythrocyte Sedimentation Rate mm 33.0 ± 3.6 30.3 ± 3.0 33.9 ± 3.4 28.5 ± 3.1a
SGPT IU/L 26.3 ± 2.6 23.6 ± 1.7 22.9 ± 2.1 19.9 ± 1.3
Creatinine mg/dl 0.97 ± 0.03 0.93 ± 0.03 1.17 ± 0.21 0.93 ± 0.03
Data expressed as a mean ± SEM.
There was no difference between baseline and week 8 values for the treatment groups with the exception of erythrocyte sedimentation rate as 
denoted by the letter a (p < 0.05). As the analysis was done on a paired basis completion of the protocol was necessary, hence the analysis is per 
protocol, glucosamine n = 41, reparagen n = 38.BMC Complementary and Alternative Medicine 2007, 7:34 http://www.biomedcentral.com/1472-6882/7/34
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Secondary Efficacy Variables – Global Assessments, 
Tolerance
Global assessments of the treatment were obtained at the
conclusion of the 8 week treatment protocol, using both
investigator and subject perspectives. Investigators
reported a score of excellent (the highest level) for 97% of
the glucosamine treated subjects, and 92% for reparagen.
These values were not significantly different. Subjects'
assessments were based on a willingness to continue with
the treatments. For both reparagen and glucosamine sul-
fate 95% of subjects stated they would like to continue
treatment. Tolerability was rated by subjects as Good in
100% of the reparagen treated group, and 98% in the glu-
cosamine sulfate group.
Serum IGF-1
Serum IGF-1 levels were assessed at baseline and at the
conclusion of the 8 weeks study. Baseline values for both
glucosamine (93.4 ± 33.4 ng/ml) and reparagen (89.1 ±
32.6 ng/ml) treatment groups were comparable, indicat-
ing effective randomization. With both treatments there
was a 5% increase in serum IGF-1 (glucosamine 98.2 ±
36.6, reparagen 93.2 ± 38.2 ng/ml), which was not statis-
tically significant.
Use of Rescue Medication
The rescue medication was paracetamol (acetomi-
nophen). Consumption was relatively consistent
throughout the study (Fig. 8), despite a reported decline
in symptoms. However, significantly fewer paracetamol
tablets were consumed in the reparagen group versus glu-
cosamine at each assessment period, and for the total
study (p < 0.01).
Sequential changes in WOMAC pain scores for reparagen  (red, n = 48) and glucosamine sulfate (blue, n = 47) Figure 3
Sequential changes in WOMAC pain scores for reparagen 
(red, n = 48) and glucosamine sulfate (blue, n = 47). Both 
treatments resulted in a significant reduction in WOMAC 
pain levels within one week of treatment (p < 0.001) com-
pared to baseline values. Sustained administration resulted in 
a time-dependent decrease in pain scores (p < 0.001)
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Table 4: Response rates of subjects to treatment based on pain assessments.
4 Weeks 8 Weeks
Criteria Glucosamine
(n = 47)
Reparagen
(n = 48)
Glucosamine
(n = 47)
Reparagen
(n = 48)
20% decrease in WOMAC pain 74.5 81.2 89.4 93.7
20% decrease in WOMAC pain & 10 mm VAS Pain 66.0 68.7 85.1 91.7
50% decrease in WOMAC pain 38.2 58.3* 72.3 77.1
50% decrease in WOMAC pain & 20 mm VAS Pain 25.5 37.5 63.8 72.9
Percentage of subjects meeting various criteria for response to treatment. Results between reparagen (n = 48) and glucosamine sulfate (n = 47) 
were not significantly different using these criteria except where denoted by the * (P = 0.05).
Sequential response rates as determined by a 20% reduction  in the WOMAC pain scores in reparagen (red, n = 48) and  glucosamine sulfate (blue, n = 47) Figure 2
Sequential response rates as determined by a 20% reduction 
in the WOMAC pain scores in reparagen (red, n = 48) and 
glucosamine sulfate (blue, n = 47).
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Sequential changes in VAS pain scores for reparagen (red, n =  38) and glucosamine sulfate (blue, n = 41) Figure 7
Sequential changes in VAS pain scores for reparagen (red, n = 
38) and glucosamine sulfate (blue, n = 41). Both treatments 
resulted in a significant reduction in baseline VAS pain scores 
within one week (p < 0.01), with further reductions with sus-
tained administration (p < 0.001).
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Sequential changes in WOMAC function scores for repara- gen (red, n = 48) and glucosamine sulfate (blue, n = 47) Figure 5
Sequential changes in WOMAC function scores for repara-
gen (red, n = 48) and glucosamine sulfate (blue, n = 47). Both 
treatments resulted in a significant improvement in function 
within one week (reparagen p < 0.01, glucosamine p < 0.05) 
with continued improvements with sustained administration 
(p < 0.001).
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Sequential changes in WOMAC stiffness scores for repara- gen (red, n = 48) and glucosamine sulfate (blue, n = 47) Figure 4
Sequential changes in WOMAC stiffness scores for repara-
gen (red, n = 48) and glucosamine sulfate (blue, n = 47). Both 
treatments resulted in a significant reduction in baseline stiff-
ness scores from week 2 onwards (p < 0.001), but only the 
reparagen treated group was significant at week 1 (p < 0.01). 
Sustained administration resulted in a time-dependent 
decrease in stiffness scores (p < 0.001)
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Sequential changes in total WOMAC scores (pain, stiffness  and function) for reparagen (red, n = 48) and glucosamine  (blue, n = 47) Figure 6
Sequential changes in total WOMAC scores (pain, stiffness 
and function) for reparagen (red, n = 48) and glucosamine 
(blue, n = 47). Both treatments resulted in a significant 
reduction in baseline WOMAC total scores from week 1 
(reparagen p < 0.01, glucosamine p < 0.05), with further 
improvements with sustained administration (p < 0.001).
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Discussion
This study was designed to compare a new polyherbal
therapy, reparagen, with glucosamine sulfate in mild to
moderate osteoarthritis of the knee. Reparagen is derived
from South American medicinal plants and supported by
preclinical studies demonstrating chondroprotective,
cytoprotective, and anti-inflammatory properties [21-24]
as well as the ability to enhance human chondrocyte pro-
duction of the cartilage repair factor, IGF-1 [20]. Addition-
ally, one of the components of this polyherbal blend,
vincaria (Uncaria guianensis) had successfully completed a
small clinical study in osteoarthritis of the knee, with ben-
efits within a week of administration at a three-fold lower
doses than used in this trial [25].
Drop-outs from the study were at an acceptable rate, with
the majority were due to unrelated illnesses or failure to
be available for follow-up. There were no serious adverse
events that were attributable to either reparagen or glu-
cosamine, and tolerability was excellent. Subject rand-
omization was effective, with entry and basal values
equivalent in both groups and comparable to a previous
study using the same experimental design and centers
[46].
Results demonstrate that reparagen and glucosamine sul-
fate were able to elicit significant reductions in pain, stiff-
ness and functional indices of osteoarthritis disease
activity. These benefits were statistically significant within
one week of treatment using the WOMAC and VAS crite-
ria.
These observations using response rate as the primary effi-
cacy variable (Figure 2) was supported by the secondary
efficacy variables; reductions in baseline WOMAC scores,
VAS pain, global assessments of outcome by both investi-
gators and subjects were highly favorable, along with tol-
erance. Collectively, these results suggest that both
reparagen and glucosamine sulfate provide effective relief
of mild to moderate osteoarthritis of the knee in this pop-
ulation. The present study design did not include a pla-
cebo arm, and as such poses limits as to interpretation.
However, in a previous nutraceutical trial that we per-
formed in the same target population, using the same
entry criteria and comparable sites and investigators, we
noted response rates to placebo based on a 20% reduction
in WOMAC pain were substantially less (4 weeks 32%, 8
weeks 59%) than what was observed in the present study
using the same criteria [46].
Clinical trial results with glucosamine displays some vari-
ability, and the two recently performed large trials, GAIT
and GUIDE, collectively frame this issue [11,12]. Given
that in the present study we used glucosamine sulfate as a
positive comparator without a placebo group, these issues
have some bearing on the interpretation of the current
study. In the GAIT study, results with glucosamine hydro-
chloride were indistinguishable from placebo at 4 and 24
weeks [11]. In contrast, the GUIDE protocol demon-
strated that glucosamine sulfate was significantly more
effective than placebo, whereas paracetamol was marginal
in its benefits [12]. As glucosamine dose (1500 mg) was
identical in both GAIT and GUIDE studies (and the
present investigation) it is clear that total dose does not
explain these variations. The present study does differ
from both GUIDE and GAIT in terms of the timing and
distribution of the doses. The GAIT study spread the daily
dose out over three doses whereas the GUIDE used a once
a day dosing regimen that is part of approved prescription
approach in Europe. Because we were concerned that
compliance would be compromised in this population
with three times a day dosing and additionally as we
wanted to match the dosing approach used for the ethno-
medicines in reparagen we adopted the twice a day regi-
men. For glucosamine sulfate both three times a day and
once a day regimens have clinical support for efficacy and
safety [8,9,12,39-41] suggesting that timing is not a criti-
cal determinant of efficacy, but this present report does
not include a pharmacokinetic analysis. We are not aware
of direct comparisons where glucosamine sulfate efficacy
has been evaluated with varied dosing regimens, but there
is a report describing that chondroitin sulfate in a once a
The average weekly consumption of paracetamol (acetomi- nophen) in reparagen (red, n = 38) and glucosamine sulfate  (blue, n = 41) treated subjects Figure 8
The average weekly consumption of paracetamol (acetomi-
nophen) in reparagen (red, n = 38) and glucosamine sulfate 
(blue, n = 41) treated subjects. For each time period the con-
sumption of paracetamol was lower in the reparagen treated 
group as well as cumulative consumption, depicted as week 0 
– week 8 (*, p < 0.01). Results are depicted as the average 
number of tablets (500 mg) consumed per week.
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day regimen offers a similar efficacy as multiple doses a
day [47], for the same total dose.
The magnitude of the glucosamine sulfate responses in
the present study were greater than anticipated. Without
an additional placebo arm it is difficult to frame these
findings beyond the literature. One factor to be consid-
ered is ethnicity. The GUIDE study was European and the
GAIT was performed in North America. Glucosamine sul-
fate, when administered in multiple daily doses, has pre-
viously shown to be effective in an Indian osteoarthritic
population [39]. Thus, while ethnicity needs to be enter-
tained as a factor in determining therapeutic potential,
another consideration is the cultural influence of diet.
Indian diets are characterized by the ubiquitous use of the
spice turmeric, and with it the bioactive curcumin. There
have been numerous studies that have defined an anti-
inflammatory role for curcumin suggesting that it may
offer benefits in the treatment of osteoarthritis [48-50].
These actions primarily center on the suppression of pro-
inflammatory cytokines and catabolic factors like matrix
metalloproteinases (MMPs) secondary to inhibition of
gene expression via redox-dependent transcription factors
[51,52]. Given that MMPs are responsible for the degrada-
tion of cartilage matrix and the release of glucosamine,
suppression of MMP formation with dietary curcumin
could enhance the effectiveness of supplemental glu-
cosamine. We are not aware of any study that has directly
assessed the combined actions of glucosamine and a tran-
scriptional inhibitor that regulates MMP formation, so
this conclusion remains unsupported. However, the com-
bination of the antioxidant MSM, and glucosamine sul-
fate has been reported to be additive in Indian subjects
[39]. Additionally, using markers of collagen type II
breakdown, it has been proposed that subjects that have a
high cartilage turnover may be more receptive to the ben-
efits of glucosamine [53].
This potential influence of redox active factors present in
the diet also reflects on the proposed mechanism of action
for reparagen. Studies using explants of human cartilage
indicate that catabolic degradation of cartilage matrix, a
MMP dependent response, is suppressed by reparagen in
concert with increased expression of the cartilage repair
factor, IGF-1 [20]. High levels of glucosamine (mM) in
explant studies have been shown to limit cartilage catabo-
lism but in contrast to reparagen, anabolism was also
compromised [37]. It is still unclear if this is the underly-
ing basis for the benefits if glucosamine as in vivo admin-
istration of therapeutic doses only raises blood and joint
levels to the low µM range [54-56], well below the concen-
tration required to alter catabolic activity. Nevertheless,
based on this proposed mechanism of action it would
also be likely that the combination of reparagen with glu-
cosamine sulfate may produce enhanced benefits. How-
ever, the focus of the present study, were the actions of
these agents individually, not collectively.
IGF-1 is an important anabolic repair factor for joint
health, promoting growth and repair of damaged cartilage
[23-27]. While reparagen has been shown to promote
IGF-1 production in cartilage explants, and negate the
suppressive effects of IL-1β on IGF-1 production by
chondrocytes [17], it is difficult to assess these events in a
clinical trial. Serum levels of IGF-1 were assessed and were
increased by 5% with either treatment, an effect that was
not significant. Serum IGF-1 levels are thought to reflect
hepatic production, and it is unknown as to what level
changes in joint production would be reflected in circulat-
ing levels. From this study there does not appear to be a
strong link between serum IGF-1 and joint health. How-
ever, it is worth noting however, that serum IGF-1 levels
were low in this population when compared to large pop-
ulation studies in other settings [57-60]. Indeed, serum
IGF-1 levels in this group were more reflective of subjects
that were 20 years older. The reasons for this are unclear
as the subjects were otherwise in good health and while
rheumatic heart disease is associated with reduced serum
IGF-1, rheumatoid arthritis is not [61]. It is also unknown
if low serum IGF-1 levels enhances the effectiveness of
reparagen or glucosamine, however, it does not appear to
preclude their efficacy. Thus, we conclude that serum IGF-
1 levels in absolute numbers or in terms of changes with
intervention, were not predictive of outcome in these sub-
jects.
A number of studies have compared glucosamine sulfate
with non-steroidal anti-inflammatory drugs like ibupro-
fen as positive controls [37-39], without the inclusion of
a placebo group. The advantage of this approach is that
need for rescue medication is less and the data may not be
as clouded by the mixed effects of both treatment and res-
cue medication. In these studies the outcomes generally
reflect a favorable response to glucosamine sulfate in
terms of safety and efficacy and have contributed to the
growing interest in the nutraceutical management of
arthritis. Nevertheless using glucosamine sulfate as a pos-
itive comparator is a controversial design given that the
literature debates the effectiveness of different glu-
cosamine formulations.
A consistent outcome was that reparagen treatment was
associated with a reduction in the use of the rescue medi-
cation. (Fig. 8, p < 0.01). The lower consumption of para-
cetamol was significant at each assessment interval during
the protocol. Given the concerns associated with excessive
paracetamol consumption on liver function [48] or the
deleterious effects of non-steroidal anti-inflammatory
drugs (NSAIDs) on gastrointestinal, renal and cardiovas-
cular function [62-65], the reduced paracetamol con-BMC Complementary and Alternative Medicine 2007, 7:34 http://www.biomedcentral.com/1472-6882/7/34
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sumption with reparagen is worth noting. Additionally,
the vincaria component of reparagen has been shown to
block the severe gastrointestinal complications associated
with high dose NSAIDs [21,23]. Thus, not only is this
botanical component effective in treating arthritis it may
also limit the side-effects of common pharmaceutical
approaches to managing arthritis. In 28 day sub-acute
safety and toxicity studies, reparagen displayed no evi-
dence of toxicity and was given the top OECD safety rating
of 5 or unclassifiable. The excellent tolerability and safety
profile seen in this study confirms these OECD safety and
toxicity studies and is consistent with the cultural history
of safe use of the parent medicinal plants.
Conclusion
Reparagen and glucosamine sulfate both produced a
steady reduction in osteoarthritis symptoms, particularly
pain, with continued improvements upon sustained treat-
ment. Use of the rescue medication was significantly less
in reparagen subjects, but otherwise responses were com-
parable between reparagen and glucosamine sulfate
groups. Both investigational agents were well tolerated
and safe. Reparagen should be considered an effective
option in the management of osteoarthritis, particularly
for those subjects with seafood allergy or diabetes.
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